- Home
- DGICA vs OCS Comparison
DGICA vs OCS Comparison
Compare DGICA & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- OCS
- Stock Information
- Founded
- DGICA 1986
- OCS 2003
- Country
- DGICA United States
- OCS Switzerland
- Employees
- DGICA N/A
- OCS N/A
- Industry
- DGICA Property-Casualty Insurers
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- OCS Health Care
- Exchange
- DGICA Nasdaq
- OCS Nasdaq
- Market Cap
- DGICA 682.8M
- OCS 689.8M
- IPO Year
- DGICA N/A
- OCS N/A
- Fundamental
- Price
- DGICA $19.72
- OCS $18.58
- Analyst Decision
- DGICA Hold
- OCS Strong Buy
- Analyst Count
- DGICA 1
- OCS 4
- Target Price
- DGICA $18.00
- OCS $31.50
- AVG Volume (30 Days)
- DGICA 119.7K
- OCS 30.4K
- Earning Date
- DGICA 04-24-2025
- OCS 05-08-2025
- Dividend Yield
- DGICA 3.70%
- OCS N/A
- EPS Growth
- DGICA 1206.68
- OCS N/A
- EPS
- DGICA 2.03
- OCS N/A
- Revenue
- DGICA $993,637,805.00
- OCS $847,333.00
- Revenue This Year
- DGICA $5.29
- OCS $49.27
- Revenue Next Year
- DGICA $5.85
- OCS $1,920.31
- P/E Ratio
- DGICA $9.69
- OCS N/A
- Revenue Growth
- DGICA 5.29
- OCS N/A
- 52 Week Low
- DGICA $12.26
- OCS $10.79
- 52 Week High
- DGICA $20.51
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- DGICA 60.30
- OCS 54.68
- Support Level
- DGICA $19.39
- OCS $18.01
- Resistance Level
- DGICA $20.03
- OCS $19.50
- Average True Range (ATR)
- DGICA 0.67
- OCS 0.77
- MACD
- DGICA 0.05
- OCS 0.17
- Stochastic Oscillator
- DGICA 67.22
- OCS 66.30
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.